Latest news

New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL

Dublin, Ireland, 17 November 2022: ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual property for commercial and/or research use in China. ATLATL will now provide access to the foundational CRISPR/Cas9 Intellectual Property held by Dr. Emmanuelle Charpentier. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Eighty-nine patents are held in over eighty countries. The ATLATL Center for Innovation & Research is a global innovation research and development center located in the heart of multiple prestigious science

Read more <i class="fal fa-long-arrow-right"></i>

Top news